LY-01019

Primary objective: To evaluate the safety and tolerability of LY01019 injection in patients with advanced solid tumors, observe dose-limiting toxicity (DLT), explore the maximum tolerated dose (MTD), and determine the recommended dose (RP2D) for phase II clinical trials. Secondary objective: To evaluate the pharmacokinetic characteristics (PK), immunogenicity and preliminary efficacy of LY01019 injection in patients with advanced solid tumors and various tumor indication cohorts. Exploratory objectives: (1) To observe the relationship between the exposure of LY01019 injection and receptor occupancy, the PD-L1 receptor occupancy rate (RO) on the surface of T cells in whole blood after administration, and the concentration of TGF-β1 in blood; (2) To explore the correlation between PD-L1 expression in tumor tissue and the anti-tumor activity of LY01019 injection; to explore the correlation between the state of peripheral blood immune cells and the anti-tumor activity of LY01019 injection.